Mosaic Biosciences, a Boulder, CO-based protein and antibody discovery company that helps its partners identify next-generation therapies for the prevention and treatment of disease, raised $11.4m in funding.
The round was led by Telegraph Hill Partners with participation from Dan Mitchell, a Boulder-based venture capitalist. Jeanette Welsh and Rob Capone from Telegraph Hill Partners will join Mosaic’s Board concurrent with the financing, and Deval Lashkari from Telegraph Hill Partners will join as a Board observer. Dan Mitchell and Eric Furfine, Chief Executive and Scientific Officer at Mosaic, will also hold seats on the Mosaic Board.
The growth financing will be used to expand lab facility infrastructure, develop new technologies and capabilities, augment the business development team, and expand the breadth of its scientific team.
Led by Marty Stanton, Chief Executive and Operating Officer, Mosaic is a protein and antibody discovery company that helps its partners identify next-generation therapies for the prevention and treatment of disease. Mosaic teams provide comprehensive, end-to-end discovery services, including program assessment and strategy development; program management; antibody discovery and optimization; protein production, purification, and characterization; protein engineering; biochemical and cellular assay development; formulation, stability and developability studies; bioanalytical (PK and PD) assay development; and clinical candidate-validating pharmacology. Partners include biopharmaceutical companies, startup companies, and University seed and venture capital funds.
FinSMEs
15/06/2022